Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Advaxis Inc (NQ: ADXS )

0.8299 USD -0.0523 (-5.93%)
Official Closing Price Updated: 7:59 PM EST, Mar 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Advaxis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
From GlobeNewswire News Releases
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program 
From GlobeNewswire News Releases
Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
From GlobeNewswire News Releases
Advanced Testing Options Help Alter the Fight Against Cancer
FinancialBuzz.com News Commentary 
From PR Newswire
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
From GlobeNewswire News Releases
Advaxis, Inc. Announces Pricing of $8 Million Public Offering
From GlobeNewswire News Releases
Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
From GlobeNewswire News Releases
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From GlobeNewswire News Releases
Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
From GlobeNewswire News Releases
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
From GlobeNewswire News Releases
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
From GlobeNewswire News Releases
Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
From GlobeNewswire News Releases
Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update
From GlobeNewswire News Releases
Advaxis Announces Resignation of Chief Financial Officer
From GlobeNewswire News Releases
Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference
From GlobeNewswire News Releases
Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
From GlobeNewswire News Releases
Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners
From GlobeNewswire News Releases
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
From GlobeNewswire News Releases
Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020
From GlobeNewswire News Releases
Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
From GlobeNewswire News Releases
Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update
From GlobeNewswire News Releases
Advaxis to Present at the 2020 LD Micro Virtual Conference
From GlobeNewswire News Releases
Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference
From GlobeNewswire News Releases
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
From GlobeNewswire News Releases
Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
From GlobeNewswire News Releases
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program 
From Business Wire News Releases
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
From GlobeNewswire News Releases
Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
From GlobeNewswire News Releases
Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering
From GlobeNewswire News Releases
Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
ADXS-504 is the Company’s second drug product candidate from the HOT program to receive IND clearance from FDA 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.